MacroGenics Inc
MGNX1.595USD
+0.015+0.95%
交易中 （美東）報價延遲15分鐘
100.63M總市值
虧損本益比TTM
關於 MacroGenics Inc 公司
MacroGenics, Inc. 是一家生物製藥公司，專注於開發和商業化用於治療癌症的單克隆抗體療法。該公司的產品候選藥物管線主要來自其基於抗體的技術平臺套件，這些平臺適用於廣泛的治療領域。該公司正在開發針對各種腫瘤相關抗原和免疫檢查點分子的產品候選藥物。其領先的管線項目是 vobramitamab duocarmazine (vobra duo)，這是一種抗體-藥物偶聯物 (ADC)，靶向 B7-H3，B7-H3 是 B7 家族免疫調節蛋白中的一種分子，由幾種不同的腫瘤類型表達。其臨牀管線包括兩種基於其雙特異性 DART 技術的候選產品，該技術可同時與 PD-1 和其他檢查點分子結合。這些候選藥物包括 lorigerlimab 和 tebotelimab。此外，該公司正在開發雙特異性 DART 分子 MGD024。該公司還在開發各種其他項目。
公司簡介
公司代碼MGNX
公司名稱MacroGenics Inc
上市日期Oct 10, 2013
CEODr. Scott Koenig, M.D., Ph.D.
員工數量341
證券類型Ordinary Share
年結日Oct 10
公司地址9704 Medical Center Drive
城市ROCKVILLE
上市交易所NASDAQ Global Select Consolidated
國家United States of America
郵編20850
電話13012515172
網址https://www.macrogenics.com/
公司代碼MGNX
上市日期Oct 10, 2013
CEODr. Scott Koenig, M.D., Ph.D.
公司高階主管
名稱
名稱/職務
職務
持股
持股變動
Dr. Scott Koenig, M.D., Ph.D.
Dr. Scott Koenig, M.D., Ph.D.
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
1.37M
+45.23%
Mr. James Karrels
Mr. James Karrels
Chief Financial Officer, Senior Vice President, Corporate Secretary
Chief Financial Officer, Senior Vice President, Corporate Secretary
186.80K
--
Mr. Edward (Ed) Hurwitz, J.D.
Mr. Edward (Ed) Hurwitz, J.D.
Independent Director
Independent Director
44.07K
+17.30%
Dr. Stephen L. Eck, M.D., Ph.D.
Dr. Stephen L. Eck, M.D., Ph.D.
Senior Vice President - Clinical Development, Chief Medical Officer
Senior Vice President - Clinical Development, Chief Medical Officer
29.38K
--
Mr. Thomas Spitznagel, Ph.D.
Mr. Thomas Spitznagel, Ph.D.
Senior Vice President - Technical Operations
Senior Vice President - Technical Operations
21.40K
+157.36%
Mr. William K. Heiden
Mr. William K. Heiden
Independent Chairman of the Board
Independent Chairman of the Board
11.00K
+144.44%
Dr. Margaret A. Liu, M.D.
Dr. Margaret A. Liu, M.D.
Independent Director
Independent Director
11.00K
+144.44%
Dr. Ezio Bonvini, M.D.
Dr. Ezio Bonvini, M.D.
Senior Vice President - Research, Chief Scientific Officer
Senior Vice President - Research, Chief Scientific Officer
--
--
Mr. Scott T. Jackson
Mr. Scott T. Jackson
Independent Director
Independent Director
--
--
Mr. Eric Risser
Mr. Eric Risser
Chief Operating Officer
Chief Operating Officer
--
--
查看更多
名稱
名稱/職務
職務
持股
持股變動
Dr. Scott Koenig, M.D., Ph.D.
Dr. Scott Koenig, M.D., Ph.D.
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
1.37M
+45.23%
Mr. James Karrels
Mr. James Karrels
Chief Financial Officer, Senior Vice President, Corporate Secretary
Chief Financial Officer, Senior Vice President, Corporate Secretary
186.80K
--
Mr. Edward (Ed) Hurwitz, J.D.
Mr. Edward (Ed) Hurwitz, J.D.
Independent Director
Independent Director
44.07K
+17.30%
Dr. Stephen L. Eck, M.D., Ph.D.
Dr. Stephen L. Eck, M.D., Ph.D.
Senior Vice President - Clinical Development, Chief Medical Officer
Senior Vice President - Clinical Development, Chief Medical Officer
29.38K
--
Mr. Thomas Spitznagel, Ph.D.
Mr. Thomas Spitznagel, Ph.D.
Senior Vice President - Technical Operations
Senior Vice President - Technical Operations
21.40K
+157.36%
Mr. William K. Heiden
Mr. William K. Heiden
Independent Chairman of the Board
Independent Chairman of the Board
11.00K
+144.44%
收入明細
暫無數據
暫無數據
業務
地區
暫無數據
股東統計
更新時間: 7月9日 週三
更新時間: 7月9日 週三
持股股東
股東類型
持股股東
持股股東
佔比
Bellevue Asset Management AG
15.74%
Armistice Capital LLC
9.98%
BlackRock Institutional Trust Company, N.A.
7.13%
The Vanguard Group, Inc.
7.02%
Wasatch Global Investors Inc
5.15%
Other
54.98%
持股股東
持股股東
佔比
Bellevue Asset Management AG
15.74%
Armistice Capital LLC
9.98%
BlackRock Institutional Trust Company, N.A.
7.13%
The Vanguard Group, Inc.
7.02%
Wasatch Global Investors Inc
5.15%
Other
54.98%
股東類型
持股股東
佔比
Investment Advisor
35.01%
Investment Advisor/Hedge Fund
21.21%
Hedge Fund
20.14%
Private Equity
5.03%
Individual Investor
3.10%
Research Firm
2.87%
Pension Fund
0.53%
Bank and Trust
0.10%
Family Office
0.02%
Other
12.00%
機構持股
更新時間: 7月1日 週二
更新時間: 7月1日 週二
報告期間
機構數
持股數
持股佔比
持股變動
2025Q2
350
55.50M
87.97%
-21.64M
2025Q1
365
56.04M
88.82%
-21.64M
2024Q4
367
57.72M
91.98%
-20.16M
2024Q3
367
57.51M
91.64%
-21.39M
2024Q2
370
63.01M
100.47%
-16.59M
2024Q1
368
67.02M
107.12%
-8.36M
2023Q4
353
64.08M
103.25%
-12.72M
2023Q3
352
60.31M
97.24%
-15.19M
2023Q2
356
62.23M
100.48%
-18.91M
2023Q1
389
60.87M
98.46%
-22.53M
查看更多
股東持股明細
名稱
持股數
佔比
持股變動
變動比例
公告日期
Bellevue Asset Management AG
9.93M
15.74%
--
--
Jun 01, 2025
Armistice Capital LLC
6.30M
9.98%
+20.00K
+0.32%
Mar 31, 2025
BlackRock Institutional Trust Company, N.A.
4.50M
7.13%
-147.34K
-3.17%
Mar 31, 2025
The Vanguard Group, Inc.
4.43M
7.02%
+109.31K
+2.53%
Mar 31, 2025
Wasatch Global Investors Inc
3.25M
5.15%
-238.25K
-6.83%
Mar 31, 2025
Frazier Life Sciences Management, L.P.
3.18M
5.03%
--
--
Mar 31, 2025
Acadian Asset Management LLC
2.31M
3.66%
+1.02M
+78.84%
Mar 31, 2025
Millennium Management LLC
1.72M
2.73%
-1.14M
-39.81%
Mar 31, 2025
Two Sigma Investments, LP
1.72M
2.73%
-256.25K
-12.95%
Mar 31, 2025
Geode Capital Management, L.L.C.
1.46M
2.31%
+22.97K
+1.60%
Mar 31, 2025
查看更多
持股ETF
更新時間: 8月2日 週六
更新時間: 8月2日 週六
機構名稱
佔比
iShares Micro-Cap ETF
0.02%
ProShares Ultra Nasdaq Biotechnology
0.01%
iShares Biotechnology ETF
0.01%
Invesco Nasdaq Biotechnology ETF
0.01%
Vanguard US Momentum Factor ETF
0%
DFA Dimensional US Core Equity Market ETF
0%
Fidelity Nasdaq Composite Index ETF
0%
SPDR S&P Biotech ETF
0%
Goldman Sachs ActiveBeta US Small Cap Equity ETF
0%
iShares Genomics Immunology and Healthcare ETF
0%
查看更多
iShares Micro-Cap ETF
佔比0.02%
ProShares Ultra Nasdaq Biotechnology
佔比0.01%
iShares Biotechnology ETF
佔比0.01%
Invesco Nasdaq Biotechnology ETF
佔比0.01%
Vanguard US Momentum Factor ETF
佔比0%
DFA Dimensional US Core Equity Market ETF
佔比0%
Fidelity Nasdaq Composite Index ETF
佔比0%
SPDR S&P Biotech ETF
佔比0%
Goldman Sachs ActiveBeta US Small Cap Equity ETF
佔比0%
iShares Genomics Immunology and Healthcare ETF
佔比0%
分紅派息
近5年累計派現
0.00
美元
公告日期
分紅計劃
股權登記日
現金發放日
除權除息日
暫無數據
拆合股
公告日期
類型
比率
暫無數據
公告日期
類型
比率
暫無數據
